RT Journal Article
SR Electronic
T1 Overcoming COVID-19 vaccine preferential bias in Europe: Is the end of the pandemic still foreseeable?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.23.21259422
DO 10.1101/2021.06.23.21259422
A1 Frank Adusei-Mensah
A1 Ivy Eyiah Inkum
YR 2021
UL http://medrxiv.org/content/early/2021/06/28/2021.06.23.21259422.abstract
AB The availability of safe and effective vaccine alone does not save lives; it is the inoculation plus other public health measures that do. Recent reports suggest the growing trend in vaccine preferential bias in parts of the world but not much in Europe. The present paper aims to investigate the occurrence of COVID-19 vaccine preferential bias in Europe for effective vaccination planning and pandemic control.Method Data on vaccine delivered and vaccination campaigns of the EU member states was collected from Eu center for disease control (EUCDC) on COVID-19 vaccination radar. The data was processed for analysis on MS excel and both descriptive and statistical analysis was done with IBM’s SPSS version 21. Analysis was performed at 95% confidence interval and statistically significant difference was considered at p < 0.05.Results We observed statistically significantly lower vaccine uptake compared to the vaccine delivered doses in the present study (average at 62.678 +/-3.928%) (p< 0.05, CI = 95%). Great variances in uptake for Oxford-AstraZeneca vaccines (50.927 +/-4.626 %) compared to Pfizer-Biontech vaccine (86.285 +/- 2.1052 %) was observed compared to previous prospective study on the wiliness to receive COVID-19 vaccine in the region (75%).Conclusion Public health practitioners and policy makers need to factor the existence of COVID-19 preferential bias based on vaccine type or manufacturer. This will enable them introduce policies including public educational campaigns to overcome biasness on the wiliness to inoculate thereby enhancing vaccine uptake for smooth and effective control of the pandemic.Competing Interest StatementThe researchers have no competing interest in carrying out this study.Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Permission for use of the data was grantedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll necessary data have been included